PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35178649-5 2022 Resveratrol-treated AML-12 hepatocytes showed reduced ratio of the following key metabolic factors: phosphorylated PP2A to total PP2A (pPP2A/PP2A), pAKT/AKT, pFOXO1/FOXO1 and pAMPK/AMPK, indicating inhibition of AKT and AMPK, but activation of PP2A and FOXO1. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 115-119 34257688-6 2021 In insulin-resistant HepG2 cells, the administration of a PP2A activator or CaMKKbeta inhibitor attenuated the effects of resveratrol, but the administration of an AMPK inhibitor abolished the effects of resveratrol. Resveratrol 122-133 protein phosphatase 2 phosphatase activator Homo sapiens 58-62 35178649-5 2022 Resveratrol-treated AML-12 hepatocytes showed reduced ratio of the following key metabolic factors: phosphorylated PP2A to total PP2A (pPP2A/PP2A), pAKT/AKT, pFOXO1/FOXO1 and pAMPK/AMPK, indicating inhibition of AKT and AMPK, but activation of PP2A and FOXO1. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 129-133 35178649-5 2022 Resveratrol-treated AML-12 hepatocytes showed reduced ratio of the following key metabolic factors: phosphorylated PP2A to total PP2A (pPP2A/PP2A), pAKT/AKT, pFOXO1/FOXO1 and pAMPK/AMPK, indicating inhibition of AKT and AMPK, but activation of PP2A and FOXO1. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 135-145 35178649-5 2022 Resveratrol-treated AML-12 hepatocytes showed reduced ratio of the following key metabolic factors: phosphorylated PP2A to total PP2A (pPP2A/PP2A), pAKT/AKT, pFOXO1/FOXO1 and pAMPK/AMPK, indicating inhibition of AKT and AMPK, but activation of PP2A and FOXO1. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 244-248 35178649-11 2022 Resveratrol changes the circadian expression of metabolic and clock genes activating the fasting state and inducing the PP2A-FOXO1-PEPCK pathway. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 120-124 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 104-115 protein phosphatase 2 phosphatase activator Homo sapiens 14-18 30066962-0 2019 Resveratrol inhibits Erk1/2-mediated adhesion of cancer cells via activating PP2A-PTEN signaling network. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 77-81 30066962-5 2019 Further research revealed that both protein phosphatase 2A (PP2A) and phosphatase and tensin homolog (PTEN)-Akt were implicated in resveratrol-inactivated Erk1/2-dependent cell adhesion. Resveratrol 131-142 protein phosphatase 2 phosphatase activator Homo sapiens 60-64 33605996-5 2021 Moreover, RSV activates protein phosphatase 2A (PP2A), which binds and dephosphorylates TFEB, promoting its nuclear translocation and the expression of TFEB target genes required for autophagosome and lysosomal biogenesis. Resveratrol 10-13 protein phosphatase 2 phosphatase activator Homo sapiens 32-46 33605996-5 2021 Moreover, RSV activates protein phosphatase 2A (PP2A), which binds and dephosphorylates TFEB, promoting its nuclear translocation and the expression of TFEB target genes required for autophagosome and lysosomal biogenesis. Resveratrol 10-13 protein phosphatase 2 phosphatase activator Homo sapiens 48-52 33605996-7 2021 Taken together, these data link RSV-induced ER calcium signaling, PP2A and TFEB activation to promote autophagy and lysosomal function, by which RSV may trigger a cellular self-defense mechanism that effectively mitigate lipid accumulation commonly associated with many metabolic diseases. Resveratrol 32-35 protein phosphatase 2 phosphatase activator Homo sapiens 66-70 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 104-115 protein phosphatase 2 phosphatase activator Homo sapiens 76-80 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 104-115 protein phosphatase 2 phosphatase activator Homo sapiens 76-80 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 243-254 protein phosphatase 2 phosphatase activator Homo sapiens 14-18 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 243-254 protein phosphatase 2 phosphatase activator Homo sapiens 76-80 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 243-254 protein phosphatase 2 phosphatase activator Homo sapiens 76-80 30066962-8 2019 Furthermore, inhibition of mechanistic/mammalian target of rapamycin (mTOR) with rapamycin or silencing mTOR enhanced resveratrol"s inhibitory effects on the basal and IGF-1-induced inhibition of PP2A-PTEN, activation of Akt-Erk1/2, and cell adhesion. Resveratrol 118-129 protein phosphatase 2 phosphatase activator Homo sapiens 196-205 30066962-9 2019 The results indicate that resveratrol inhibits Erk1/2-mediated adhesion of cancer cells via activating PP2A-PTEN signaling network. Resveratrol 26-37 protein phosphatase 2 phosphatase activator Homo sapiens 103-107 29062069-0 2017 Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Resveratrol 0-11 protein phosphatase 2 phosphatase activator Homo sapiens 74-78 29062069-3 2017 Here we show that resveratrol, a polyphenol, significantly induces PP2A activity and reduces Tau phosphorylation at PP2A-dependent epitopes. Resveratrol 18-29 protein phosphatase 2 phosphatase activator Homo sapiens 67-71 29062069-3 2017 Here we show that resveratrol, a polyphenol, significantly induces PP2A activity and reduces Tau phosphorylation at PP2A-dependent epitopes. Resveratrol 18-29 protein phosphatase 2 phosphatase activator Homo sapiens 116-120 26146868-6 2015 Interestingly, resveratrol potently rescued the cells from Cd-induced suppression of protein phosphatases 2A (PP2A) and 5 (PP5) activity. Resveratrol 15-26 protein phosphatase 2 phosphatase activator Homo sapiens 110-121 26146868-7 2015 Over-expression of PP2A or PP5 strengthened the inhibitory effects of resveratrol on Cd-induced activation of Erk1/2 and/or JNK, as well as cell death. Resveratrol 70-81 protein phosphatase 2 phosphatase activator Homo sapiens 19-23 26146868-8 2015 The results indicate that resveratrol prevents Cd-induced activation of Erk1/2 and JNK pathways and neuronal cell death in part via activating PP2A and PP5. Resveratrol 26-37 protein phosphatase 2 phosphatase activator Homo sapiens 143-147